WAT

Waters Corporation (WAT) - 10-K Summary for Fiscal Year Ended December 31, 2006

Business Context and Reporting Period

This filing covers the fiscal year ended December 31, 2006. Waters Corporation is a leading manufacturer of analytical instruments, operating through two primary divisions: the Waters Division (High Performance Liquid Chromatography, Ultra Performance Liquid Chromatography, and Mass Spectrometry) and the TA Division (Thermal Analysis and Rheometry). The Company serves pharmaceutical, life science, industrial, academic, and government customers globally. Approximately 68% of net sales in 2006 were generated outside the United States.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 11% to $1.28 billion, driven by the introduction of new products (ACQUITY UPLC, Quattro Premier XE, SQD, TQD, Synapt HDMS) and strong growth in Asia (19% increase). Pharmaceutical customer spending rebounded after a weak 2005.
• Profitability: Operating income rose 4% to $295.2 million. This growth was partially offset by $28.0 million in additional stock-based compensation costs due to the adoption of SFAS No. 123(R) and $8.5 million in restructuring charges.
• Acquisitions: The Company completed three acquisitions in 2006: Environmental Resources Associates (ERA) for $62.5 million, VICAM for $13.8 million, and Thermometrics for $2.5 million. These added approximately $26.5 million in sales for the year.
• Stock Repurchases: The Company repurchased 5.8 million shares for $249.2 million in 2006. Cumulative repurchases under the 2005 program reached 11.3 million shares ($465.3 million).
• Debt Structure: Total debt increased to $885.0 million to fund share repurchases and acquisitions. In January 2007, the Company refinanced its credit facilities, expanding capacity to $1.1 billion.

Guidance, Outlook, and Risks

• Outlook: Management expects ERA to add approximately $17.0 million in sales in 2007. VICAM sales are expected to reach $10.0 million, and Thermometrics sales $4.0 million in 2007. Capital expenditures for 2007 are expected to be similar to 2006 levels.
• Restructuring: A cost reduction plan initiated in February 2006 (terminating 74 employees) is expected to yield approximately $7.4 million in annual cost savings. No further charges are expected from this initiative.
• Key Risks:
  • Customer Concentration: Approximately 52% of sales are to the pharmaceutical and biotechnology industries, which are subject to capital spending fluctuations.
  • Foreign Exchange: 68% of sales are denominated in foreign currencies; a stronger U.S. dollar could materially adversely affect results.
  • Competition: Intense competition from global manufacturers (e.g., Agilent, Thermo Fisher, Shimadzu) on performance and price.
  • Legal Proceedings: Ongoing patent litigation with Agilent/HP in France and Germany, though a settlement was reached regarding the UK claim in February 2006.

Investor Verification Checklist

• Stock-Based Compensation Impact: Verify the sustainability of earnings given the $28.8 million expense from SFAS 123(R) adoption, which reduced diluted EPS by $0.20.
• Inventory Levels: Review the $29.9 million increase in inventory, attributed to new product ramp-ups and outsourcing transitions, to ensure no obsolescence risks.
• Debt Covenants: Confirm compliance with the new 2007 Credit Agreement covenants (Interest Coverage Ratio ≥ 3.50:1; Leverage Ratio ≤ 3.25:1).
• Pharma Spending Trends: Monitor capital expenditure trends in the pharmaceutical sector, which represents over half of the Company's revenue.
• Acquisition Integration: Assess the integration progress and revenue contribution of the ERA, VICAM, and Thermometrics acquisitions against management's 2007 projections.